利用标准临床磁共振成像表观扩散系数图像预测胶质瘤的基因型与生存:来自癌症基因组图谱的初步研究
本初步研究回顾性分析癌症基因组图谱中131例成人弥漫性胶质瘤的术前MRI及ADC图,评估影像特征与ADC对IDH突变、1p/19q共缺失、MGMT启动子甲基化及总生存的预测价值。IDH野生型胶质瘤更常表现为强化、坏死和水肿,且平均相对ADC更低;以平均相对ADC 1.08为界值,无论WHO分级,IDH突变型和IDH野生型中平均相对ADC较低者生存更差;IDH突变型中平均相对ADC较低亚组的生存与IDH野生型相似。
要点
- IDH野生型胶质瘤更常见强化、坏死、水肿及>50%强化面积,少见囊性区,平均相对ADC更低。
- 平均相对ADC以1.08为界值,IDH突变型和IDH野生型中低于此值者生存均更差。
- IDH突变型中平均相对ADC较低亚组的生存与IDH野生型胶质瘤无显著差异。
核心结论
- IDH野生型胶质瘤平均相对ADC更低,且低ADC与IDH突变型和IDH野生型胶质瘤的不良生存相关,与组织学分级无关;IDH突变型中平均相对ADC较低亚组的生存与IDH野生型相似。
研究设计与样本
- 初步研究,回顾性分析癌症基因组图谱中131例成人弥漫性胶质瘤患者的术前MRI及ADC图,评估影像特征和平均相对ADC对IDH突变、1p/19q共缺失、MGMT启动子甲基化及总生存的预测价值。
关键影像表现/征象
- IDH野生型胶质瘤较IDH突变型更倾向于表现为强化、坏死和水肿。
- IDH野生型胶质瘤中强化面积>50%者更多(P<.001),无囊性区者更多(P=.013)。
- IDH野生型胶质瘤平均相对ADC中位数为1.1,IDH突变型为1.6(P<.001)。
诊断标准与关键数值
- 以平均相对ADC 1.08为界值,IDH突变型中低于1.08者中位生存24.2个月(95%CI 0.0-54.9个月),高于1.08者为62.0个月(P=.003)。
- 以平均相对ADC 1.08为界值,IDH野生型中低于1.08者中位生存10.4个月(95%CI 4.4-16.4个月),高于1.08者为17.7个月(95%CI 11.6-23.7个月;P=.041)。
- IDH突变型中平均相对ADC较低者的中位生存与IDH野生型胶质瘤无显著差异。
临床应用与阅片要点
- 阅片时可结合强化、坏死、水肿、强化面积比例及囊性区有无等特征提示IDH野生型可能。
- 测量平均相对ADC(取最低ADC区域内ROI)有助于提示IDH状态及生存分层。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Few studies have shown MR imaging features and ADC correlating with molecular markers and survival in patients with glioma. Our purpose was to correlate MR imaging features and ADC with molecular subtyping and survival in adult diffuse gliomas.
MATERIALS AND METHODS: Presurgical MRIs and ADC maps of 131 patients with diffuse gliomas and available molecular and survival data from The Cancer Genome Atlas were reviewed. MR imaging features, ADC (obtained by ROIs within the lowest ADC area), and mean relative ADC values were evaluated to predict isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion status, MGMT promoter methylation, and overall survival.
RESULTS: IDH wild-type gliomas tended to exhibit enhancement, necrosis, and edema; >50% enhancing area (P < .001); absence of a cystic area (P = .013); and lower mean relative ADC (median, 1.1 versus 1.6; P < .001) than IDH-mutant gliomas. By means of a cutoff value of 1.08 for mean relative ADC, IDH-mutant and IDH wild-type gliomas with lower mean relative ADC (<1.08) had poorer survival than those with higher mean relative ADC (median survival time, 24.2 months; 95% CI, 0.0-54.9 months versus 62.0 months; P = .003; and median survival time, 10.4 months; 95% CI, 4.4-16.4 months versus 17.7 months; 95% CI, 11.6-23.7 months; P = .041, respectively), regardless of World Health Organization grade. Median survival of those with IDH-mutant glioma with low mean relative ADC was not significantly different from that in those with IDH wild-type glioma. Other MR imaging features were not statistically significant predictors of survival.
CONCLUSIONS: IDH wild-type glioma showed lower ADC values, which also correlated with poor survival in both IDH-mutant and IDH wild-type gliomas, irrespective of histologic grade. A subgroup with IDH-mutant gliomas with lower ADC had dismal survival similar to that of those with IDH wild-type gliomas.
引用
- Wu CC, Jain R, Radmanesh A, et al. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas. AJNR Am J Neuroradiol. 2018. PMID: 30190259. doi:10.3174/ajnr.A5794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。